Investor Relations

Stock Quote - Ticker Tape

 

SEC Filings

  o View CEL-SCI's SEC Filings  
       

Corporate Presentations & Interviews

  February 22, 2015
Exclusive Interview with Geert Kersten from the floor of the NYSE

 
  February 20, 2015
Listen to CEO Participation in Ascendiant's Quarterly Management Discussion

 
  February 9, 2015
Presentation at 2015 BIO CEO & Investor Conference

 
  January 12, 2015
Presentation at Biotech Showcase 2015  

 

Warrant Quote

  o NYSE MKT: CVM WS  

 

Press Releases

  o All Press Releases  
 
  MARCH 3, 2015
NEW STORY CEL-SCI Reports 2nd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial
  FEBRUARY 27, 2015
NEW STORY CEL-SCI Completes Key Milestone with Clearance to Conduct Phase III Trial in 21 Countries
  FEBRUARY 20, 2015
NEW STORY CEL-SCI to Participate in Ascendiant's Quarterly Management Discussion Series Today, Friday February 20 at 11 AM Eastern Time
  FEBRUARY 19, 2015
NEW STORY CEL-SCI's Phase III Head and Neck Cancer Trial Cleared to Begin Patient Enrollment in Malaysia, the 20th Country to Join the Trial
  FEBRUARY 18, 2015
NEW STORY CEL-SCI to Present At 3rd Annual Sachs Cancer Bio Partnering and Investment Forum
  FEBRUARY 11, 2015
NEW STORY The Philippines is the 19th Country to Clear CEL-SCI for Patient Enrollment in Its Phase III Head and Neck Cancer Trial
  FEBRUARY 6, 2015
NEW STORY CEL-SCI Corporation Reports First Quarter 2015 Financial Results
  FEBRUARY 5, 2015
NEW STORY CEL-SCI to Present at 17th Annual BIO CEO & Investor Conference
  FEBRUARY 2, 2015
NEW STORY CEL-SCI Reports Record Monthly Patient Enrollment in Its Phase III Head and Neck Cancer Trial
  JANUARY 26, 2015
NEW STORY CEL-SCI Receives Regulatory Clearance to Expand Its Phase III Head and Neck Cancer Trial into Romania
  JANUARY 9, 2015
NEW STORY CEL-SCI to Present at Biotech Showcase 2015
  JANUARY 6, 2015
NEW STORY Date Set For Arbitration Trial between CEL-SCI And Clinical Research Organization Inventiv
  JANUARY 5, 2015
NEW STORY CEL-SCI's 2014 Patient Enrollment Increases Eight-Fold Over 2013 in Its Phase III Head and Neck Cancer Trial
  DECEMBER 23, 2014
NEW STORY CEL-SCI Reports Fiscal 2014 Financial Results and Clinical & Corporate Developments
  DECEMBER 8, 2014
CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head and Neck Cancer Trial with Addition of 7 More Clinical Sites
 

Investor Relations Contact

   

Gavin de Windt
Phone: +1 703-506-9460
E-mail: gdewindt@cel-sci.com